Secreted phospholipases A2, a new class of HIV inhibitors that block virus entry into host cells

Journal of Clinical Investigation

Volumn 104, Issue 5, 1999, Pages 611-618

  Fenard, David ^a   Lambeau, Gérard ^b   Valentin, Emmanuel ^b   Lefebvre, Jean Claude ^a   Lazdunski, Michel ^b   Doglio, Alain ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NIGEXINE; PHOSPHOLIPASE A2; SNAKE VENOM; TAIPOXIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG MECHANISM; DRUG POTENCY; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION; CATALYSIS; CONTROLLED STUDY; ENZYME INHIBITION; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS ATTACHMENT; VIRUS ENTRY;

EID: 0032701519     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6915     Document Type: Article

References (59)

1. Dalgleish, A.G., et al. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 312:763-767.
2. Klatzmann, D., et al. 1984. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 312:767-768.
3. Alkhatib, G., et al. 1996. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1955-1958.
4. Deng, H., et al. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:661-666.
5. Dragic, T., et al. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR5. Nature. 381:667-673.
6. Feng, Y., Broder, C.C., Kennedy, P.E., and Berger, E.A. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 272:872-877.
7. Moore, J.P., Trkola, A., and Dragic, T. 1997. Co-receptors for HIV-1 entry. Curr. Opin. Immunol. 9:551-562.
8. Littman, D.R. 1998. Chemokine receptors: keys to AIDS pathogenesis? Cell. 93:677-680.
9. Chan, D.C., and Kim, P.S. 1998. HIV entry and its inhibition. Cell. 93:681-684.
10. Stevenson, M. 1996. Portals of entry: uncovering HIV nuclear transport pathways. Trends Cell. Biol. 6:9-15.
11. Bukrinsky, M.I., et al. 1993. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature. 365:666-669.
12. Gallay, P., Swingler, S., Song, J., Bushman, F., and Trono, D. 1995. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of inregrase. Cell. 83:569-576.
13. Gallay, P., Hope, T., Chin, D., and Trono, D. 1997. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc. Natl. Acad. Sci. USA. 94:9825-9830.
14. Jacque, J.M., et al. 1998. Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase. EMBO J. 17:2607-2618.
15. Cocchi, F., et al. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 270:1811-1815.
16. Oberlin, E., et al. 1996. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 382:833-835.
17. Schols, D., Este, J.A., Henson, G., and De, C.E. 1997. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res. 35:147-156.
18. Doranz, B.J., et al. 1997. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186:1395-1400.
19. Pakker, N.G., et al. 1998. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat. Med. 4:208-214.
20. Autran, B., et al. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 277:112-116.
21. Perelson, A.S., et al. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 387:188-191.
22. 2. Toxicon. 27:613-635.
23. 2. Annu. Rev. Biochem. 64:653-688.
24. 2 superfamily of signal transduction enzymes. Trends Biochem. Sci. 22:1-2.
25. 2. Crit. Rev. Immunol. 17:225-283.
26. 2 gene family in mammals. J. Biol. Chem. 272:17247-17250.
27. 2. Trends Pharmacol. Sci. 20:162-170.
28. 2. J. Biol. Chem. 272:15745-15752.
29. 2. J. Biol. Chem. 274:19152-19160.
30. 2 enzymes: structure, function and mechanism. R.M. Kini, editor. John Wiley & Sons. Chichester, United Kingdom. 389-412.
31. Lambeau, G., Barhanin, J., Schweitz, H., Qar, J., and Lazdunski, M. 1989. Identification and properties of very high affinity brain membrane-binding sites for a neurotoxic phospholipase from the taipan venom. J. Biol. Chem. 264:11503-11510.
32. 2 in different tissues. Neurochem. Res. 16:651-658.
33. 2 receptor. Prog. Lipid Res. 34:117-138.
34. 2 receptor-deficient mice. J. Biol. Chem. 272:32792-32797.
35. 2 are natural ligands of the mouse M-type receptor. J. Biol. Chem. 274:7043-7051.
36. 2 expression and inflammation: the relationship with associated disease states. J. Lipid Mediat. 8:1-30.
37. Martin, I., and Ruysschaert, J.M. 1995. Lysophosphatidylcholine inhibits vesicles fusion induced by the NH2-terminal extremity of SIV/HIV fusogenic proteins. Biochim. Biophys. Acta. 1240:95-100.
38. Gunther, A.S., and Stegmann, T. 1997. How lysophosphatidylcholine inhibits cell-cell fusion mediated by the envelope glycoprotein of human immunodeficiency virus. Virology. 235:201-208.
39. 2 from cobra venom with cytotoxic properties not related to esterase activity. Purification, amino acid sequence, and biological properties. J. Biol. Chem. 264:13289-13297.
40. 2 from Heloderma suspectum. Eur. J. Biochem. 196:537-544.
41. 2 variant, from Bothrops asper snake venom. Nat. Toxins. 3:26-31.
42. Charneau, P., et al. 1994. HIV-1 reverse transcription. A termination step at the center of the genome. J. Mol. Biol. 241:651-662.
43. Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369.
44. Maréchal, V., Clavel, F., Heard, J.M., and Schwartz, O. 1998. Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J. Virol. 72:2208-2212.
45. Wu, L., et al. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 384:179-183.
46. Aloia, R.C., Tian, H., and Jensen, F.C. 1993. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc. Natl. Acad. Sci. USA. 90:5181-5185.
47. Owman, C., et al. 1998. The leukotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. Proc. Natl. Acad. Sci. USA. 95:9530-9534.
48. 2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell. 81:957-966.
49. Pleskoff, O., Seman, M., and Alizon, M. 1995. Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus-cell fusion but not on cell-cell fusion. J. Virol. 69:570-574.
50. Popov, S., et al. 1998. Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J. 17:909-917.
51. Schwartz, O., Marechal, V., Danos, O., and Heard, J.M. 1995. Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J. Virol. 69:4053-4059.
52. Aiken, C. 1997. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J. Virol. 71:5871-5877.
53. Tokunaga, K., et al. 1998. Inhibition of human immunodeficiency virus type 1 virion entry by dominant-negative Hck. J. Virol. 72:6257-6259.
54. Bukovsky, A.A., Weimann, A., Accola, M.A., and Gottlinger, H.G. 1997. Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence. Proc. Natl. Acad. Sci. USA. 94:10943-10948.
55. Braaten, D., Franke, E.K., and Luban, J. 1996. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J. Virol. 70:3551-3560.
56. Pandori, M.W., et al. 1996. Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J. Virol. 70:4283-4290.
57. Aiken, C., and Trono, D. 1995. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J. Virol. 69:5048-5056.
58. Swingler, S., et al. 1997. The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix. J. Virol. 71:4372-4377.
59. Stranford, S.A., et al. 1999. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc. Natl. Acad. Sci. USA. 96:1030-1035.